| Article Access Statistics|
| Viewed||2173 |
| Printed||87 |
| Emailed||0 |
| PDF Downloaded||59 |
| Comments ||[Add] |
| Cited by others ||1 |
Click on image for details.
|LETTER TO EDITOR
|Year : 2011 | Volume
| Issue : 3 | Page : 260
Andrea Tendas1, Luca Cupelli1, Laura Scaramucci1, Massimiliano Palombi1, Malgorzata Monika Trawinska1, Marco Giovannini1, Gregorio Antonio Brunetti2, Claudio Cartoni2, Francesco Bondanini3, Paolo de Fabritiis1, Pasquale Niscola1
1 Hematology Unit, S. Eugenio Hospital, Rome, Italy
2 Hematology, Department of Cellular Biotechnologies and Hematology, University "La Sapienza", Rome, Italy
3 Laboratory Medicine, "Sandro Pertini" Hospital, Rome, Italy
|Date of Web Publication||28-Jan-2012|
Hematology Unit, S. Eugenio Hospital, Rome
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Tendas A, Cupelli L, Scaramucci L, Palombi M, Trawinska MM, Giovannini M, Brunetti GA, Cartoni C, Bondanini F, de Fabritiis P, Niscola P. Authors' reply. Indian J Palliat Care 2011;17:260
|How to cite this URL:|
Tendas A, Cupelli L, Scaramucci L, Palombi M, Trawinska MM, Giovannini M, Brunetti GA, Cartoni C, Bondanini F, de Fabritiis P, Niscola P. Authors' reply. Indian J Palliat Care [serial online] 2011 [cited 2020 Sep 23];17:260. Available from: http://www.jpalliativecare.com/text.asp?2011/17/3/260/92357
The recent comment by Wiwanitkit  to our paper on anticoagulant (AC) and antiplatelet (AP) agents in the management of hematological malignancies in a home-care program  was valuable and interesting.
The author concluded, "This is no doubt the reason why the use of AC/AP in home healthcare seems to be uncommon in this report"  and "There appears to be a high incidence of complications or adverse events of AC/AP drugs in clinical practice and, therefore, the use of these drugs in home healthcare for cases with hematological malignancies might be considered a risk".  Our opinion, however, is that firstly the frequency of use of the AC/AP in our case series is difficult to evaluate, being not properly comparable with similar realities, given the heterogeneity of both patients and AC/AP treatment indications; secondly, even the frequency of hemorrhagic complications there seems at least not higher than that observed in similar populations of patients.  Therefore, we believe that it is at least hasty to conclude that the use of AC/AP therapy in our series has been more limited than expected due to an excessive rate of bleeding complications.
Finally, we are extremely favorable to the dissemination and patient use of point-of-care testing (POCT) analyzer systems, while not believing that this should necessarily favor the spread of the use of AC/AP in home managed hematological patients.
| » References|| |
|1.||Wiwanitkit V. Anticoagulants and anti-platelet agents in palliative home healthcare. Indian J Palliat Care 2011;17:260. |
|2.||Tendas A, Cupelli L, Scaramucci L, Palombi M, Trawinska MM, Giovannini M, et al. Anticoagulant and anti-thrombotic treatments in the management of hematological malignancies in a home care program. Indian J Palliat Care 2011;17:54-6. |
|3.||Cartoni C, Niscola P, Breccia M, Brunetti G, D'Elia GM, Giovannini M, et al. Hemorrhagic complications in patients with advanced hematological malignancies followed at home: An Italian experience. Leuk Lymphoma 2009;50:387-91. |
|This article has been cited by|
| ||Tendas, A. and Cupelli, L. and Scaramucci, L. and Palombi, M. and Trawinska, M.M. and Giovannini, M. and Brunetti, G.A. and Cartoni, C. and Bondanini, F. and De Fabritiis, P. and Niscola, P. |
| ||Indian Journal of Palliative Care. 2011; 17(3): 260-261 |